There are no Transcripts on MBLTY.
Wed, Apr. 9, 8:45 AM| Comment!
Oct. 11, 2013, 8:03 AM
- Osiris Therapeutics (OSIR) soars 20% premarket.
- The company is selling its mesenchymal stem cell business (including the Phase 3 stem cell therapeutic Prochymal) to Mesoblast Limited (MBLTY.PK).
- OSIR will receive a $50M closing and asset transfer consideration (recorded in Q4) and up to $50M in potential clinical and regulatory milestone payments.
- Due to the release of around $14M in deferred tax assets, OSIR expects to report a profit for the current fiscal year. (PR)
Jul. 8, 2011, 1:58 PM
Jan. 10, 2011, 8:54 AM
Dec. 8, 2010, 7:44 AMCephalon (CEPH) will pay $220M for a 20% stake in Mesoblast (MBLTY.PK) and the right to market the Aussie company’s adult stem-cell therapies for heart and nervous system conditions. Cephalon will pay up to another $1.7B in milestone payments as the therapies move towards commercialization. | Comment!
MBLTY vs. ETF Alternatives
Mesoblast is developing a series of high margin, off-the-shelf adult stem cell products that are obtained from a single donor, commercially expanded and frozen, and subsequently used in potentially thousands of unrelated, or allogeneic, recipients at the time and place of need.
Other News & PR